Cancer Genetics, Inc. and ICON have entered into an agreement to offer biotech and pharmaceutical clients access to ICON Laboratory Services, combined with Cancer Geneticâ€™s expertise in oncology testing and genomic assay development.
The partnership will provide clients access to combined expertise ranging from complex, oncology-focused genomic testing to core central laboratory analysis, project and data management and sample logistics on a global basis.
Oncology testing services are the core focus area for both CGI and ICON Laboratory Services. Together, the two companies will leverage their respective expertise to provide key insights to the oncology drug development and clinical trial process. The partnership is focused on providing a comprehensive, integrated and efficient solution for laboratory testing for global oncology trials from Phase I through Phase IV.
â€œWe are looking forward to working with the CGI team and to enhancing our client offering with complementary laboratory service programs,â€ said James Miskel, utive Vice President, ICON Laboratory Services. â€œTogether, CGI and ICON are uniquely positioned to provide a full range of comprehensive lab solutions for our customers with current and future oncology-focused clinical trials.â€
With the projected value of the cancer diagnostics market estimated to reach US$169B globally by 2020, the industry has growing demand for complex oncology laboratory testing services. CGI provides complex genomic testing for six out of ten major pharmaceutical companies in the US.
â€œThis partnership will satisfy the enormous need among biotech and pharmaceutical companies for more efficient and comprehensive testing solutions by integrating CGI’s specialised, genomic testing to ICONâ€™s laboratory solutions, â€œsaid Panna Sharma, CEO of Cancer Genetics.â€